Filing Flows › Xeris Biopharma Holdings (XERS) › Net income
Xeris Biopharma Holdings (XERS) net income by quarter
Xeris Biopharma Holdings' net income was $11.3M in Q3 2026 (third quarter 2026), +405% from Q1 2026. Over the last 4 quarters it ranged from $621K (Q3 2025) to $11.3M (Q3 2026).
| Quarter | Net income | Q/Q | Y/Y |
|---|---|---|---|
| Q3 2026 | $11.3M | +405% | 18× |
| Q1 2026 | $2.2M | -80% | — |
| Q4 2025 | $11.1M | 18× | — |
| Q3 2025 | $621K | — | — |
Q3 2026 at a glance
Xeris Biopharma Holdings, Q3 2026: revenue $107M (+44% year over year), operating margin 15.8%, net earnings $11.3M, operating cash flow $35.5M. The chart follows the revenue to costs, profit and cash.
Questions
What is Xeris Biopharma Holdings' net income?
Xeris Biopharma Holdings' net income was $11.3M in Q3 2026 (third quarter 2026), +405% from Q1 2026.
How has Xeris Biopharma Holdings' net income changed?
Over the last 4 quarters it ranged from $621K (Q3 2025) to $11.3M (Q3 2026).
Q3 2026 results → · How Xeris Biopharma Holdings makes money →